The effect of platelet activation on the hypercoagulability induced by murine monoclonal antiphospholipid antibodies

Antiphospholipid antibodies are associated with an increased risk of thrombosis. Findings of this study suggest that platelet activation reinforces the hypercoagulability induced by interference of antiphospholipid antibodies/target complexes with coagulation reactions on membrane surfaces. Background To identify the mechanisms of the hypercoagulability associated with antiphospholipid antibodies, we investigated antibody-mediated platelet activation and interference of antibodies with phospholipid-dependent reactions. Design and Methods We used two murine monoclonal antibodies, one against β2-glycoprotein I (7F6G), the other against prothrombin (28F4). Platelet activation was assessed by phospholipid-related platelet procoagulant activity. Endogenous thrombin potential without activated protein C (ETP0) and the activated protein C concentration that reduced the ETP0 by 50% (IC50-APC) were determined by calibrated automated thrombography. Results Both monoclonal antibodies mimicked the effect of IgG in 11 out of a series of 40 patients with antiphospholipid antibodies in thrombography. In the presence of their target, 7F6G and 28F4 at 200 μg/mL exhibited comparatively low and high binding to platelets and elicited low and high levels of procoagulant phospholipids on platelet surface, respectively. In platelet-poor plasma, these antibodies induced a 1.6 and >12-fold increase in IC50-APC, respectively, thus providing evidence for a procoagulant effect independent of platelet activation. The 84% decrease in ETP0 indicated that 28F4 also displayed an anticoagulant effect. In platelet-rich plasma, this anticoagulant effect was significantly less (23% decrease in ETP0), demonstrating that a high increase in procoagulant surfaces by platelet activation significantly antagonizes the anticoagulant effect of antiphospholipid antibodies. In both types of plasma, the inhibition of thrombin generation (reduced ETP0) was less than the inhibition of activated protein C activity (increased IC50-APC). Conclusions Our findings show that platelet activation reinforces the hypercoagulability induced by competition between antiphospholipid antibodies/target complexes and pro- and anticoagulant complexes for phospholipid surfaces.

[1]  H. Coenraad Hemker,et al.  Calibrated Automated Thrombin Generation Measurement in Clotting Plasma , 2003, Pathophysiology of Haemostasis and Thrombosis.

[2]  P. Hogg,et al.  Beta2‐glycoprotein I in thrombosis: evidence for a role as a natural anticoagulant , 1996, British journal of haematology.

[3]  H. Hemker,et al.  Phenotyping the haemostatic system by thrombography--potential for the estimation of thrombotic risk. , 2004, Thrombosis research.

[4]  J. Mustard,et al.  Preparation of Suspensions of Washed Platelets from Humans , 1972, British journal of haematology.

[5]  C. Esmon,et al.  Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-{beta}2-glycoprotein I monoclonal antibodies. , 2005, Blood.

[6]  H. Hemker,et al.  Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. , 1999, Blood.

[7]  Naomi,et al.  On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. , 1995, The Journal of clinical investigation.

[8]  P. Joshua,et al.  Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. , 2001, Blood.

[9]  T. Barbui,et al.  Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. , 2003, Blood.

[10]  C. Male,et al.  The presence of IgG antibodies against β2‐glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant , 2005, Journal of thrombosis and haemostasis : JTH.

[11]  G. M. Iverson,et al.  Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. , 2006, Arthritis and rheumatism.

[12]  J. Vermylen,et al.  Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. , 2003, Blood.

[13]  H. Hemker,et al.  A Chromogenic Test to Determine the Procoagulant Phospholipids in Platelet-rich Plasma and Whole Blood , 1994, Thrombosis and Haemostasis.

[14]  S. Rahgozar,et al.  Current concepts on the pathogenesis of the antiphospholipid syndrome. , 2007, Blood.

[15]  Urbaniak,et al.  IgG from patients with antiphospholipid syndrome binds to platelets without induction of platelet activation , 1998, British journal of haematology.

[16]  H. Hemker,et al.  Initiating and potentiating role of platelets in tissue factor‐induced thrombin generation in the presence of plasma: subject‐dependent variation in thrombogram characteristics , 2004, Journal of thrombosis and haemostasis : JTH.

[17]  P. D. de Groot,et al.  Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? , 1993, Blood.

[18]  J. Kelton,et al.  Serum-induced platelet procoagulant activity: an assay for the characterization of prothrombotic disorders. , 1999, The Journal of laboratory and clinical medicine.

[19]  H. Hemker,et al.  Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk. , 2007, Haematologica.

[20]  K. Fujikawa,et al.  Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. , 1989, The Journal of biological chemistry.

[21]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[22]  Yves Gruel,et al.  Platelet activation induced by human antibodies to interleukin-8. , 2003, Blood.

[23]  T. Byzova,et al.  Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation. , 1997, The Journal of biological chemistry.

[24]  T. Barbui,et al.  Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. , 2007, Blood.

[25]  B. Roussel,et al.  Measurement of anti-phospholipid antibodies by ELISA using beta 2-glycoprotein I as an antigen. , 1991, Journal of immunological methods.

[26]  R. Derksen,et al.  Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? , 1993 .

[27]  P. D. de Groot,et al.  Dimers of β2-Glycoprotein I Increase Platelet Deposition to Collagen via Interaction with Phospholipids and the Apolipoprotein E Receptor 2′* , 2003, Journal of Biological Chemistry.

[28]  L. Vallar,et al.  β2-glycoprotein I Binding to Platelet Microparticle Membrane Specifically Reduces Immunoreactivity of Glycoproteins IIb/IIIa , 2001, Thrombosis and Haemostasis.

[29]  J. Vermylen,et al.  Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease , 2003, Journal of thrombosis and haemostasis : JTH.

[30]  F. Guillemin,et al.  Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—A meta-analysis , 1997, Lupus.

[31]  G. FitzGerald,et al.  Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. , 1997, The Journal of clinical investigation.

[32]  T. Barbui,et al.  Anti‐prothrombin IgG from patients with anti‐phospholipid antibodies inhibits the inactivation of factor Va by activated protein C , 2005, British journal of haematology.

[33]  C. Sáez,et al.  Circulating platelet-derived microparticles in systemic lupus erythematosus , 2005, Thrombosis and Haemostasis.

[34]  S. Nomura,et al.  Significance of Anti-oxidized LDL Antibody and Monocyte-derived Microparticles in Anti-phospholipid Antibody Syndrome , 2003, Autoimmunity.

[35]  J. Hanly,et al.  Anti-beta2-glycoprotein I autoantibodies, in vitro thrombin generation, and the antiphospholipid syndrome. , 2000, The Journal of rheumatology.